Lannett Expand its Partnership with HEC to Include Biosimilar Fast-Acting Insulin

 Lannett Expand its Partnership with HEC to Include Biosimilar Fast-Acting Insulin

Lannett Expand its Partnership with HEC to Include Biosimilar Fast-Acting Insulin

Shots:

  • The companies collaborated to co-develop Insulin aspart while Lannett granted exclusive US commercialization rights of insulin aspart to HEC
  • Lannett will fund the clinical development requirements and will manage the clinical & regulatory steps specific for the FDA’s approval while HEC continues to develop the product and related manufacturing infrastructure. Both companies will share the profits of the venture
  • Insulin aspart is a short-acting (fast-acting) insulin typically taken just before eating, is used to treat adults with T1D & T2D

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Lannett Company

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post